Lifetime Risk of Cardiovascular Disease Among Individuals With and Without Diabetes Stratified by Obesity Status in the Framingham Heart Study
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
OBJECTIVE—We assessed the lifetime risk of cardiovascular disease (CVD) among individuals with and without obesity and diabetes. RESEARCH DESIGN AND METHODS—Participants were drawn from the original and offspring cohorts of the Framingham Heart Study. Lifetime (30-year) risk of CVD was assessed using a modified Kaplan-Meier approach adjusting for the competing risk of death, beginning from age 50 years. RESULTS—Over 30 years, the lifetime risk of CVD among women with diabetes was 54.8% among normal-weight women and 78.8% among obese women. Among normal-weight men with diabetes, the lifetime risk of CVD was 78.6%, whereas it was 86.9% among obese men. CONCLUSIONS—The lifetime risk of CVD among individuals with diabetes is high, and this relationship is further accentuated with increasing adiposity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Individuals with type 2 diabetes have a lifetime risk of CAD that includes 67% of women and 78% of men and is exacerbated by obesity ( 22 , 80 , 165 ).”
From Exercise and Type 2 Diabetes (2010) · cites this paper as [80]
Experimental — accuracy not yet measuredIn the citing paper
“In the Framingham Heart Study, Fox [7] reported that, along with the increasing T2DM prevalence, the attributable risk of CVD due to T2DM increased from 5.4% in the period 1952–1974 to 8.7% in the period 1975 and 1998.”
From Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017 (2018) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lifetime risk for diabetes mellitus in the United States
Narayan, K. M. V. (2003) · JAMA · doi:10.1001/jama.290.14.1884 · Cited by 1,515
Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age
Lloyd-Jones, D. M., Leip, E. P., Larson, M. G., D’Agostino, R. B., Beiser, A., Wilson, P. W. F., Wolf, P. A., & Levy, D. (2006) · Circulation · doi:10.1161/circulationaha.105.548206 · Cited by 1,298 · cited 1×
“The lifetime risk of coronary heart disease is 42% among men and 25% among women (2) and is higher among individuals with diabetes (3).”
Self-citationLifetime risk of developing coronary heart disease
Lloyd-Jones, D. M., Larson, M. G., Beiser, A., & Levy, D. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10279-9 · Cited by 929
Increasing Cardiovascular Disease Burden Due to Diabetes Mellitus: The Framingham Heart Study
Fox, C. S., Coady, S., Sorlie, P. D., D’Agostino, R. B., Pencina, M. J., Vasan, R. S., Meigs, J. B., Levy, D., & Savage, P. J. (2007) · Circulation · doi:10.1161/circulationaha.106.658948 · Cited by 656
Self-citationImpact of Recent Increase in Incidence on Future Diabetes Burden
Narayan, K. M. V., Boyle, J. P., Geiss, L. S., Saaddine, J. B., & Thompson, T. J. (2006) · Diabetes Care · doi:10.2337/dc06-1136 · Cited by 602
Effect of BMI on Lifetime Risk for Diabetes in the U.S.
Narayan, K. M. V., Boyle, J. P., Thompson, T. J., Gregg, E. W., & Williamson, D. F. (2007) · Diabetes Care · doi:10.2337/dc06-2544 · Cited by 510
Gaynor, J. J., Feuer, E. J., Tan, C. C., Wu, D. H., Little, C. R., Straus, D. J., Clarkson, B. D., & Brennan, M. F. (1993) · Journal of the American Statistical Association · doi:10.1080/01621459.1993.10476289 · Cited by 483 · cited 2×
“For computing the 10, 20, and 30-year risks, we used the Practical Incidence Estimators (PIE) macro approach developed by Beiser et al (4) based on a method proposed by Gaynor et al (5) as previously described (6).”
Beiser, A., D'Agostino, R. B., Seshadri, S., Sullivan, L. M., & Wolf, P. A. (2000) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(20000615/30)19:11/12<1495::aid-sim441>3.0.co;2-e · Cited by 186
Self-citationEstimated Risks for Developing Obesity in the Framingham Heart Study
Vasan, R. S., Pencina, M. J., Cobain, M., Freiberg, M. S., & D'Agostino, R. B. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-7-200510040-00005 · Cited by 158
Self-citationTemporal Trends in BMI Among Adults With Diabetes
Leibson, C. L., Williamson, D. F., Melton, L. J., Palumbo, P. J., Smith, S. A., Ransom, J. E., Schilling, P. L., & Narayan, K. M. V. (2001) · Diabetes Care · doi:10.2337/diacare.24.9.1584 · Cited by 112 · cited 1×
“The prevalence of obesity among individuals with diabetes continues to rise (1).”
Cited by
Items 101–200 of 246
Colberg, S. R., Sigal, R. J., Fernhall, B., Regensteiner, J. G., Blissmer, B. J., Rubin, R. R., Chasan‐Taber, L., Albright, A. L., & Braun, B. (2010) · Cited by 21
Fonseca, V. A. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.11.005 · Cited by 19
Sjöstrand, M., Iqbal, N., Lu, J., & Hirshberg, B. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.05.006 · Cited by 21
Jeong, E., Park, N., Kim, Y., Jeon, J. Y., Chung, W. Y., & Yoon, D. (2020) · Scientific Reports · doi:10.1038/s41598-020-62482-1 · Cited by 20
Medveczky, D., Kodsi, R., Skelsey, K., Grudzinskas, K., Bueno, F. R., Ho, V., Kormas, N., & Piya, M. K. (2020) · Journal of Diabetes Research · doi:10.1155/2020/9327910 · Cited by 21
“T2DM and obesity confer additive risk, as patients with T2DM are more likely to develop cardiovascular disease (CVD) as their BMI increases [12].”
BackgroundIncreased masked hypertension prevalence in patients with obesity
Özkan, S., Ata, N., & Yavuz, B. (2018) · Clinical and Experimental Hypertension · doi:10.1080/10641963.2018.1431262 · Cited by 20
“Obesity leads to an increase in cardiovascular risks and related diseases by acting proximal risk factors, such as hypertension dyslipidemia and diabetes (12).”
Tesfaye, A., Josef, H., Wube, T. B., Girma, Z., Negasa, B., Muche, T., & Zewude, B. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s254883 · Cited by 19
Preclinical and Clinical Data on Extraglycemic Effects of GLP-1 Receptor Agonists
Gallwitz, B. (2009) · The Review of Diabetic Studies · doi:10.1900/rds.2009.6.247 · Cited by 17
Imai, Y., Hirata, T., Saitoh, S., Ninomiya, T., Miyamoto, Y., Ohnishi, H., Murakami, Y., Iso, H., Tanaka, S., Miura, K., et al. (2020) · Hypertension Research · doi:10.1038/s41440-020-0502-5 · Cited by 17
Jafari, A., Mardani, H., Fashtali, Z. M., & Arghavan, B. (2025) · Food Science & Nutrition · doi:10.1002/fsn3.70423 · Cited by 20
Weeke, P. E., Andersson, C., Fosbøl, E. L., Brendorp, B., Køber, L., Sharma, A. M., Finer, N., James, P., Caterson, I. D., Rode, R. A., et al. (2010) · BMC Endocrine Disorders · doi:10.1186/1472-6823-10-3 · Cited by 18
“Patients enrolled under the initial inclusion criteria were required to have diagnosed T2D together with at least one defined risk factor (hypertension, dyslipidaemia, current smoker, or diabetic nephropathy), or a history of coronary vascular disease (CVD), defined as coronary artery disease, peripheral arterial occl…”
BackgroundInfluentialMedical Devices and Diagnostics for Cardiovascular Diseases in Low-Resource Settings
McGuire, H., & Weigl, B. H. (2014) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-014-9591-3 · Cited by 19
“As CVD and diabetes are closely linked, this review will focus on technologies for CVD with a secondary focus on diabetes [4].”
BackgroundDiabetes and lifetime risk of coronary heart disease
Turin, T. C., Okamura, T., Rumana, N., Afzal, A. R., Watanabe, M., Higashiyama, A., Nakao, Y. M., Nakai, M., Takegami, M., Nishimura, K., et al. (2017) · Primary care diabetes · doi:10.1016/j.pcd.2017.04.007 · Cited by 17
Baye, E., Menon, K., de Courten, M., Earnest, A., Cameron, J., & de Courten, B. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-017691 · Cited by 16
Skelley, J. W., Carter, B. S., & Roberts, M. Z. (2018) · Vascular Health and Risk Management · doi:10.2147/vhrm.s168472 · Cited by 16
“general population, ranging from 55% to 87% depending on gender and body mass index (BMI).(3) The prevalence of CVD and its potential fatality among this population”
BackgroundRafiee, M. H., & Rasool, B. K. A. (2021) · Advanced Pharmaceutical Bulletin · doi:10.34172/apb.2022.075 · Cited by 29
Iqbal, F., Shuja, M. H., Azam, L., Amjad, M., Manjee, K. Z., Ramzan, H., Sharif, T., Shoaib, A., Tahir, A., Kumar, S., et al. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.03.001 · Cited by 17
Weight Management in Type 2 Diabetes Mellitus
Siram, A. T., Yanagisawa, R. T., & Skamagas, M. (2010) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20208 · Cited by 18
Mu, W., Song, Y.-J., Yang, L., Qian, S., Yang, Q., Liu, Y., Tang, Q., & Tang, Y. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1038176 · Cited by 14
“An analysis of the Framingham Heart Study reported a positive association between obesity and the relative risks of hypertension (4).”
MethodWang, W., Qiao, J., Zhang, L., Zhang, J., Luo, J., Chen, C., Wang, X., Jia, P., Zhang, J., Pan, Q., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15763 · Cited by 13
“3,28 This study indicated that the proportion of patients with T2DM with a very high risk for CVD was associated with age and BMI.”
Iglay, K., Hannachi, H., Engel, S. S., Li, X., O’Connell, D., Moore, L. M., & Rajpathak, S. N. (2021) · Current Medical Research and Opinion · doi:10.1080/03007995.2021.1895736 · Cited by 12
Ou, H., Chen, Y., Liu, Y., & Wu, J. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.03.013 · Cited by 13
Heart rate variability and QT dispersion in a cohort of diabetes patients
Jelinek, H. F., Khandoker, A. H., Palaniswami, M. S., & McDonald, S. P. (2010) · Charles Sturt University Research Output (CRO) · Cited by 12
KNOWLEDGE OF MODIFIABLE RISK FACTORS OF HEART DISEASE AMONG PATIENTS WITH CARDIOVASCULAR RISK
Gandhi, A., Ayyappan, P., Sahana, C. L., Poovizhi, S., & Sivasakthi, K. (2016) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2017.v10i1.14180 · Cited by 12
Cobourn, C., Degboe, A., Super, P. A., Torre, M., Robinson, J., Jin, J., Furbetta, F., & Bhoyrul, S. (2013) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2013.06.010 · Cited by 12
Dabbaghi, M. M., Roudi, H. S., Safaei, R., Rahimi, V. B., Fadaei, M. R., & Askari, V. R. (2024) · Cardiovascular Toxicology · doi:10.1007/s12012-024-09921-x · Cited by 12
“Conversely, unmodifiable issues such as age, family history, and gender play variable effects [29, 30].”
Shayani, V., Voellinger, D. C., Liu, C., Cornell, C., & Okerson, T. E. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.07.2561 · Cited by 12
Obesity among type 2 diabetes mellitus at Sidama Region, Southern Ethiopia
Wube, T. B., Menjetta, T., & Nuru, M. M. (2022) · PLoS ONE · doi:10.1371/journal.pone.0266716 · Cited by 13
“It has long been established as one of the independent risk factors for CVD [11] and is associated with a different form of CVD [12–14].”
BackgroundInfluentialNelson, A. J., Pagidipati, N. J., Kelsey, M. D., Ardissino, M., Aroda, V. R., Cavender, M. A., Lópes, R. D., Al‐Khalidi, H. R., Braceras, R., Gaynor, T., et al. (2022) · American Heart Journal · doi:10.1016/j.ahj.2022.10.079 · Cited by 11
Kamon, T., Kaneko, H., Itoh, H., Kiriyama, H., Mizuno, Y., Morita, H., Takeda, N., Yamamichi, N., & Komuro, I. (2021) · International Heart Journal · doi:10.1536/ihj.20-654 · Cited by 11
Hipertensão em mulheres presas no Brasil: muito além do biológico
da Silva, P. N., Kendall, C., da Silva, A. Z., Mota, R. M. S., Araújo, L. F., Neto, R. D. J. P., Júnior, F. M. L. P., Macena, R. H. M., & Kerr, L. R. F. S. (2023) · Ciência & Saúde Coletiva · doi:10.1590/1413-81232023281.10672022 · Cited by 20
“O excesso de peso corporal está associado a au-tabela 28 .”
BackgroundPeterson, G. M. (2012) · Annals of Medicine · doi:10.3109/07853890.2011.653392 · Cited by 11
Cheng, C., Xue, F., Sui, W., Meng, L., Xie, L., Zhang, C., Yang, J., & Zhang, Y. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16931 · Cited by 9
Mukherjee, J., Sternhufvud, C., Smith, N., Bell, K. F., Stott‐Miller, M., McMorrow, D., & Johnston, S. S. (2016) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2016.22.5.449 · Cited by 10
Zhang, X., Lin, S., Zeng, Q., Peng, L., & Yan, C. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1612369 · Cited by 19
Yamamoto, Y., Ikeue, K., Kanasaki, M., Yamakage, H., Oishi, K., Mori, T., Satoh‐Asahara, N., Masuda, I., & Ishii, K. (2024) · Scientific Reports · doi:10.1038/s41598-024-78541-w · Cited by 8
“As previous studies reported, among individuals with obesity, those with hypertension have a higher mortality risk 23 and those with diabetes mellitus have a higher lifetime risk of cardiovascular diseases 24 .”
Zhang, G., Dong, S., & Wang, L. (2025) · BMC Public Health · doi:10.1186/s12889-025-23075-7 · Cited by 9
The Obesity Paradox of Cardiovascular Outcomes in Patients with Diabetes Mellitus
Thakker, J., Khaliq, I., Ardeshna, N. S., Lavie, C. J., & Oktay, A. A. (2025) · Current Diabetes Reports · doi:10.1007/s11892-025-01592-4 · Cited by 14
“The Framingham Heart study found the lifetime CVD risk to be 78.8% in obese diabetic women and 86.9% in obese diabetic men, compared to 54.8% and 78.6% in non-obese diabetic counterparts [18].”
InfluentialNovel Relationship Between Plasmalogen Lipid Signatures and Carnosine in Humans
Mayneris‐Perxachs, J., Meikle, P. J., Mousa, A., Naderpoor, N., Fernández‐Real, J. M., & de Courten, B. V. (2021) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202100164 · Cited by 9
Diabetes and lifetime risk of stroke and subtypes in an urban middle-aged population
Turin, T. C., Okamura, T., Rumana, N., Afzal, A. R., Watanabe, M., Higashiyama, A., Nakao, Y. M., Nakai, M., Takegami, M., Nishimura, K., et al. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.02.002 · Cited by 8
Role of Herbal Active Compound in Cardiac Failure Treatment
Upadhyay, J., Amle, V. S., Trimbak, K. S., Ganesh, C. S., Pawar, K. V., Anamika, A., & Kumar, R. (2024) · Journal for Research in Applied Sciences and Biotechnology · doi:10.55544/jrasb.3.2.16 · Cited by 8
“In addition, Anemarrhenoside A-III has been reported to regulate the formation of ROS in cells and increase SOD and catalase (CAT) in a concentration-dependent manner, thus regulating intracellular oxidative homeostasis [73].”
BackgroundNADP+/NADPH in Metabolism and its Relation to Cardiovascular Pathologies
Sun, Y., Wu, D., & Hu, Q. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673275187231121054541 · Cited by 8
Obesity, diabetes, and the moving targets of healthy-years estimation
Gregg, E. W. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70242-6 · Cited by 8
What Can Tone and Entropy Tell Us about Risk of Cardiovascular Diseases?
Khandoker, A. H., Alzaabi, Y., & Jelinek, H. F. (2019) · Computing in cardiology · doi:10.22489/cinc.2019.120 · Cited by 7
Buysman, E. K., Fan, T., Blauer-Peterson, C. J., & Miller‐Wilson, L. (2018) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.19 · Cited by 7
The “Weight” of Obesity on Arterial Hypertension
Noce, A., & Daniele, N. D. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.87774 · Cited by 8
Central Obesity—More Weight in Cardiovascular Disease Prevention
Fletcher, G. F. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.01.350 · Cited by 7
Frakchi, N. E., Kinany, K. E., Baldi, M. E., Saoud, Y., & Rhazi, K. E. (2024) · PLoS ONE · doi:10.1371/journal.pone.0306038 · Cited by 8
Association of fasting plasma glucose trajectory with lifetime risk of cardiovascular disease
Li, D., Song, L., Wang, L., Chen, S., Yang, Y., Hu, Y., Wang, Y., Wu, S., & Tian, Y. (2022) · European Journal of Clinical Nutrition · doi:10.1038/s41430-022-01243-x · Cited by 6
“Some studies have demonstrated that higher FPG concentration was associated with a higher lifetime risk of CVD [6, 7].”
BackgroundSharma, P., Dilip, T. R., Mishra, U. S., & Kulkarni, A. (2023) · BMC Public Health · doi:10.1186/s12889-023-16596-6 · Cited by 8
The effectiveness of community-based programs for obesity prevention and control
Teixeira, E. (2011) · Patient Intelligence · doi:10.2147/pi.s12314 · Cited by 7
“Comorbidities are often associated with obesity, such as Type 2 Diabetes Mellitus (T2DM), asthma, sleep disorders, and cardiovascular disease (CVD).(1) The above comorbidities have a significant threat to the obese population with their high rates of both morbidly and mortality.”
Tomo, S., Sankanagoudar, S., Shukla, R. K. G., & Sharma, P. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102448 · Cited by 6
Gao, F., Zhou, Y., Yan, X., Huang, H., Liang, G., Xie, Y.-Y., Zhu, Q., Chen, Z., Wang, B., Li, H., et al. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s400970 · Cited by 5
“9% in China.(2,3) In addition, DM patients with ASCVD also had high prevalence of”
BackgroundInfluentialTibaldi, J. M. (2014) · The American Journal of the Medical Sciences · doi:10.1097/maj.0000000000000202 · Cited by 5
“Some antihyperglycemic agents have adverse effects of hypoglycemia and weight gain, which add to the already increased risk of cardiovascular disease.(5,6) Thus, an important goal in T2DM management is to achieve glycemic control without increasing the risk of hypoglycemia or weight gain.”
BackgroundFrontoni, S., Solini, A., Fioretto, P., Natali, A., Zuccalà, A., Cosentino, F., & Penno, G. (2014) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2014.01.004 · Cited by 6
Chen, W., Li, P., Wang, G., Chen, Y., Wang, B., & Chen, M. (2019) · Postgraduate Medicine · doi:10.1080/00325481.2019.1655381 · Cited by 6
“reductions in both body weight and waist circumference since obesity was an obvious risk factor for CV [45,46].”
BackgroundRisk Factors in Acute Stroke Patients With and Without Sleep Apnea
Kojić, B., Dostović, Z., Ibrahimagić, O. Ć., Smajlović, D., Hodžić, R., Iljazović, A., & Salihović, D. (2021) · Medical Archives · doi:10.5455/medarh.2021.75.444-450 · Cited by 7
“2021 DEC; 75(6): 444-450 Studies also show a correlation between the degree of oxygen desaturation during the night and increased fasting and postprandial glucose values, as well as increased insulin resistance in apnea (41).”
BackgroundKalaycı, A., Gibson, C. M., Hernandez, A. F., Hull, R. D., Cohen, A. T., Fitzgerald, C., Hussain, S. D., Chi, G., Alkhalfan, F., Harrington, R. A., et al. (2022) · Thrombosis Research · doi:10.1016/j.thromres.2022.01.016 · Cited by 5
Watanabe, D. K., Kitayama, S., Williams, D. P., & Thayer, J. F. (2025) · International Journal of Clinical and Health Psychology · doi:10.1016/j.ijchp.2025.100555 · Cited by 6
“Although our findings corroborate prior reports (Chei et al., 2007; Coe et al., 2011; Fox et al., 2008; Imai et al., 2021; Kinoshita et al., 2018; Lloyd-Jones et al., 2006; Park et al., 2020), additional examinations of cultural differences in the contribution of adiposity and inflammatory…”
Physical Activity Supports Provided by Healthcare Providers to Patients with Type 2 Diabetes
Hnatiuk, J. A., Duhamel, T. A., Katz, A., & Ready, A. E. (2012) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2012.04.009 · Cited by 6
Diabetes and cardiovascular disease: focus on glucagon-like peptide-1 based therapies
Stranges, P. M., & Khanderia, U. (2012) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098612454290 · Cited by 5
“Data from the Framingham Heart Study demonstrated a 78% lifetime risk of developing CVD in men with diabetes compared with 54.8% in men without diabetes [Fox et al. 2008].”
BackgroundInfluential▼ Empagliflozin, diabetes and outcomes
(2016) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2016.6.0411 · Cited by 4
Mana, S. T., Mahdi, D. S., & Altemimi, M. T. (2022) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/2516 · Cited by 5
Nadeau, D. A. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.09.2215 · Cited by 4
“Recent Framingham data showed the lifetime risk of CVD was higher for individuals with both diabetes and obesity.(15)”
BackgroundKhalil, C. A., & Taheri, S. (2014) · Springer eBooks · doi:10.1007/978-3-319-12766-8_12 · Cited by 4
Roh, E., Jung, H. N., Heo, J. H., Han, K., Kang, J. G., Lee, S. J., & Ihm, S. (2025) · BMJ Public Health · doi:10.1136/bmjph-2024-002020 · Cited by 3
Sodium–glucose cotransporter 2 inhibitors for the management of type 2 diabetes
Siamashvili, M., & Davis, S. N. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1967320 · Cited by 4
Genomic risk prediction of cardiovascular diseases among type 2 diabetes patients in the UK Biobank
Ye, Y., Hu, J., Pang, F., Cui, C., & Zhao, H. (2024) · Frontiers in Bioinformatics · doi:10.3389/fbinf.2023.1320748 · Cited by 6
Sudevan, R., Raj, M., Vasudevan, D., Arun, C., Thachathodiyl, R., Vijayakumar, M., Abdullakutty, J., Thomas, P., George, V., & Kabali, C. (2021) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_532_20 · Cited by 3
Hospital Diabetes Meeting 2022
Huang, J. K., Yeung, A. M., Nguyen, K. T., Xu, N. Y., Preiser, J., Rushakoff, R. J., Seley, J. J., Umpierrez, G. E., Wallia, A., Drincic, A., et al. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221110878 · Cited by 4
Effect of glitazones on the progression of coronary artery disease in type 2 diabetes patients
CHILTON, R. J. (2009) · Vascular Health and Risk Management · doi:10.2147/vhrm.s5092 · Cited by 3
“9% risk in men.(2) Overall, obesity alone was found to carry an additional 20% risk for the development of cardiovascular disease (CVD), compared to normal weight individuals.”
Šašić, B., Čanković, D., Mijatović-Jovanović, V., Ukropina, S., Ostojić, Z., Milijašević, D., Stamenković, K., & Čanković, S. (2024) · Hospital Pharmacology - International Multidisciplinary Journal · doi:10.5937/hpimj2403555s · Cited by 2
Tan, X., Liang, Y. M., Xie, L., Gutierrez, C., Harton, J. G., Muhammad, C., Swift, C., & de Havenon, A. (2025) · Current Medical Research and Opinion · doi:10.1080/03007995.2025.2577762 · Cited by 4
Lao, W., Malone, D. C., Armstrong, E., Voellinger, D. C., Somers, S. S., Jin, J., Dreyer, N. A., & GLOBE, D. R. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1059802 · Cited by 2
Palumbo, P. J., & Wert, J. (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s8564 · Cited by 2
Kountz, D. S. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1313074 · Cited by 2
“In patients with diabetes, obesity is associated with a higher lifetime risk of CV disease [8].”
BackgroundAntihyperglycemic Algorithms for Type 2 Diabetes: Focus on Nonglycemic Outcomes
Solis‐Herrera, C., Cersósimo, E., & Triplitt, C. L. (2021) · Diabetes Spectrum · doi:10.2337/ds20-0067 · Cited by 3
Is There a Role for Coronary Calcium in Patients With Diabetes?
Grundy, S. M., Vega, G. L., & Wong, N. D. (2023) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2022.12.003 · Cited by 3
What Can Tone and Entropy Tell Us About Risk of Cardiovascular Diseases
Khandoker, A. H., Alzaabi, Y., & Jelinek, H. F. (2019) · doi:10.23919/cinc49843.2019.9005542 · Cited by 2
SETHURAMAN, G., Meyyappan, C., SELVABAI, A. P., Govindaraj, A., KASI, D. D., & DURAIRAJ, G. (2022) · Indian Journal of Scientific Research · doi:10.32606/ijsr.v13.i1.00016 · Cited by 1
Garvey, W. T. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99991-5.00018-8 · Cited by 2
Amerzadeh, M., Bahrami, M., Senmar, M., Hosseinkhani, Z., & Kisomi, Z. S. (2025) · Discover Public Health · doi:10.1186/s12982-025-00403-1 · Cited by 1
“According to the Extended Parallel Processing Model, information avoidance tends to occur when individuals experience high levels of fear regarding health threats (such as the risk of a heart attack) but lack the belief that they can manage these threats effectively (i.e., low efficacy) [9, 10].”
Jung, E.-S., Choi, M.-J., Jung, S., Lee, S., Park, B., & Chae, S. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.156961 · Cited by 2
Effects of High Glucose on Simulated Ischemia/Reperfusion Injury in Isolated Cardiomyocytes
Walter, M. J. K., Shiota, M., Li, Z., Barajas, M. B., Oyama, T., & Riess, M. L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136050 · Cited by 1
“The global prevalence of T2DM and the attributable risk for CVDs due to T2DM are constantly increasing [9,10].”
Insights Into Cardiovascular Disease in Women From the Framingham Heart Study
Alexandrou, M., Parikh, N. I., Brilakis, E. S., Lloyd‐Jones, D. M., & Xanthakis, V. (2026) · JACC Advances · doi:10.1016/j.jacadv.2026.102722 · Cited by 3
Circunferencia de la cintura con sobrepeso e hipertensión arterial en adultos
Crespo, R. V. D. L. F., Martínez, R., Rodríguez, J. E. F.-B., Díaz, S. G., & Cabrera, M. J. A. (2012) · Revista Habanera de Ciencias Médicas · Cited by 1
Inkretine: Gibt es kardiovaskuläre Effekte?
Gallwitz, B. (2010) · Herz · doi:10.1007/s00059-010-3333-3 · Cited by 1
Causal inference methods to assess safety upper bounds in randomized trials with noncompliance
Wang, Y., Berlin, J. A., Pinheiro, J. C., & Wilcox, M. (2015) · Clinical Trials · doi:10.1177/1740774515572352 · Cited by 1
“The Weibull parameters were chosen to reflect an initial annual cardiovascular risk of about 2% among type 2 diabetes, which rose during follow-up with increasing age and duration of diabetes.(28,29) We chose a common a = 1.”
MethodChiasson, J., Laakso, M., & Hanefeld, M. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3314-9_10 · Cited by 1
Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes
Steinberg, H. O. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1168687 · Cited by 2
“79% and 55% in normal-weight men and women with diabetes, respectively).[74] Data from observational studies support the association of weight loss and the reduced risk of CV events in patients with T2DM.”
ResultUnderstanding the Molecular Crosstalk in Biological Processes
El-Esawi, M. A. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.77821 · Cited by 1
FUNCTIONAL STATE OF CARDIOVASCULAR SYSTEM IN YOUNG ADULTS WITH DIFFERENT BODY WEIGHT
Колінько, Л. М., & Vesnina, L. E. (2020) · Bulletin of Problems Biology and Medicine · doi:10.29254/2077-4214-2020-4-158-389-394 · Cited by 1
Shriya, A. S. K., Pawar, V. B., & Paul, A. A. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998305019240702095537 · Cited by 2
Ponce, J., Taheri, S., Lusco, V., Cornell, C., Ng‐Mak, D., Shi, R., & Okerson, T. E. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.874992 · Cited by 1
“The following sub-analyses were conducted for each assessment: (1) APEX patients; (2) HERO patients; (3) HERO, US patients (HERO-US); (4) HERO, outside the US patients (HERO-OUS); (5) US patients only (combined APEX and HERO-US); (6) BMI ( 35 to 45 kg/m(2) and 445 kg/m(2)); (7) gender (male/female); (8) age group ( 50…”
MethodProtection vasculaire chez les personnes diabétiques
Stone, J. A., Fitchett, D., Grover, S. A., Lewanczuk, R. Z., & Lin, P. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.07.013 · Cited by 1
SÍNDROME METABÓLICA E DOENÇAS CARDIOVASCULARES: DO CONCEITO AO TRATAMENTO
Ferreira, M. E. (2016) · Arquivos Catarinenses de Medicina · doi:10.63845/swbssf51 · Cited by 30
Bariatric Surgery: “Roux”-minating on Endothelial Cell and High-Density Lipoprotein Function
Brown, J. D. (2015) · Circulation · doi:10.1161/circulationaha.115.015343 · Cited by 1
“5-fold increased risk for cardiovascular disease, including myocardial infarction, stroke, and heart failure.(3,4) As obesity rates increase, the burden of obesity-associated cardiometabolic diseases on the healthcare system could be overwhelming.”
Backgrounddos Santos, J. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.7.2017.tde-17052017-111748 · Cited by 2
Risks for cardiovascular disease in middle-aged women in different social environments
Wennerholm, C. (2017) · doi:10.3384/diss.diva-140934 · Cited by 1
Delineating Signals from Association Studies
Voight, B. F. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-375142-3.10017-3
Metadata
- Authors
- Fox, C. S., Pencina, M. J., Wilson, P. W. F., Paynter, N. P., Vasan, R. S., & D’Agostino, R. B.
- Affiliations
- Brigham and Women's Hospital (US)
- Boston University (US)
- Emory University (US)
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2008-08-01
- Volume
- 31
- Issue
- 8
- Pages
- 1582-1584
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2494632
- OpenAlex
- W2154705833
- Cited by
- 247
- References
- 10
- Citations by year
- 2026: 5 · 2025: 14 · 2024: 17 · 2023: 13 · 2022: 22 · 2021: 17 · 2020: 10 · 2019: 10 · 2018: 9 · 2017: 14 · 2016: 10 · 2015: 11 · 2014: 13 · 2013: 17 · 2012: 18
- FWCI
- 10.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- OpenBU (Boston University) (submittedVersion, cc-by-nc-nd)
- Funders
- National Institutes of Health (n01hc25195-41-0-1)
- National Heart, Lung, and Blood Institute (N01‐HC25195, K24HL004334, N01-HC-025195)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Keywords
- diabetes mellitus, obesity, adiposity, sex differences, competing risk of death, Framingham Heart Study, women
- MeSH terms
- Aged, Aged, 80 and over, Cardiovascular Diseases, Female, Humans, Male, Middle Aged, Obesity, Time Factors, Risk Assessment, Diabetes Complications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.